Review



abciximab  (Eli Lilly)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Eli Lilly abciximab
    Abciximab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/abciximab/10__1155_slash_jocs_slash_3615306-93-3-5
    Average 86 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Clinical Proteomics:

    Article Title: Intraoperative Ultrasound‐Based Assessment of Coagulation in Cardiac Surgery Patients: A Single‐Center Experience
    Article Snippet: .. Channel four contains abciximab (Reopro; Eli Lilly, Indianapolis, IN) allowing determination of fbrinogen contribution to clot strength (CSF) by rendering platelets dysfunctional. ..

    other:

    Article Title: A Randomized Double-Blind Placebo-Controlled Study Comparing Intracoronary Versus Intravenous Abciximab in Patients With ST-Elevation Myocardial Infarction Undergoing Transradial Rescue Percutaneous Coronary Intervention After Failed Thrombolysis.
    Article Snippet: Please cite this article as: Olivier F. Bertrand, Éric Larose, Rodrigo Bagur, Frédéric Maes, Valérie Gaudreault, Bernard Noël, Gérald Barbeau, Jean-Pierre Déry, Charles Pirlet, Olivier Costerousse, EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASYRESCUE) PCIStudy Investigators, A Randomized Double-Blind Placebo-Controlled Study Comparing Intracoronary vs Intravenous Abciximab in Patients with ST-Elevation Myocardial Infarction Undergoing Transradial Rescue Percutaneous Coronary Intervention after Failed Thrombolysis, The American Journal of Cardiology (2018), https://doi.org/10.1016/j.amjcard.2018.03.007.

    Article Title: Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease.
    Article Snippet: Cordis, Johnson & Johnson, and Boston Scientific provided the stents; Eli Lilly provided abciximab and an unrestricted research grant; and Sanofi-Aventis and Bristol-Myers Squibb provided clopidogrel.

    Article Title: Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes
    Article Snippet: The original FREEDOM trial was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), with grants from Cordis Corporation, a Johnson & Johnson Company at the time, Boston Scientific (providing the stents), Eli Lilly (providing abciximab and an unrestricted research grant), Sanofi, and Bristol-Myers Squibb (providing clopidogrel).

    Activity Assay:

    Article Title: Megakaryocyte-induced contraction of plasma clots: cellular mechanisms and structural mechanobiology.
    Article Snippet: .. Blebbistatin (Sigma-Aldrich) was used to suppress myosin II activity, latrunculin A (Sigma-Aldrich) to inhibit actin polymerization, and abciximab (ReoPro; Eli Lilly) to block integrin αІІββ3−fibrin interactions. ..

    Blocking Assay:

    Article Title: Megakaryocyte-induced contraction of plasma clots: cellular mechanisms and structural mechanobiology.
    Article Snippet: .. Blebbistatin (Sigma-Aldrich) was used to suppress myosin II activity, latrunculin A (Sigma-Aldrich) to inhibit actin polymerization, and abciximab (ReoPro; Eli Lilly) to block integrin αІІββ3−fibrin interactions. ..

    Saline:

    Article Title: Microchip for assay of blood properties, and device for assay of blood properties
    Article Snippet: Blood was collected using a blood collection tube containing 3.2% sodium citrate, manufactured by Terumo Corporation. .. The same experiment as in Example 4-1 was carried out using (1) blood prepared by 2-fold dilution of the citrate blood with physiological saline; (2) blood prepared by adding a 0.5 U vWF (von Willebrand factor) formulation (CSL-Behring) to the 2-fold diluted blood of (1); (3) blood prepared by adding a 0.5 U PCC formulation (CSL-Behring) to the 2-fold diluted blood of (1); (4) blood prepared by adding 1 U heparin; or (5) blood prepared by adding 3 μg/ml Abciximab (Eli Lilly). .. The same experiment as in Example 4-1 was carried out using (1) blood prepared by 2-fold dilution of the citrate blood with physiological saline; (2) blood prepared by adding a 0.5 U vWF (von Willebrand factor) formulation (CSL-Behring) to the 2-fold diluted blood of (1); (3) blood prepared by adding a 0.5 U PCC formulation (CSL-Behring) to the 2-fold diluted blood of (1); (4) blood prepared by adding 1 U heparin; or (5) blood prepared by adding 3 μg/ml Abciximab (Eli Lilly).

    Formulation:

    Article Title: Microchip for assay of blood properties, and device for assay of blood properties
    Article Snippet: Blood was collected using a blood collection tube containing 3.2% sodium citrate, manufactured by Terumo Corporation. .. The same experiment as in Example 4-1 was carried out using (1) blood prepared by 2-fold dilution of the citrate blood with physiological saline; (2) blood prepared by adding a 0.5 U vWF (von Willebrand factor) formulation (CSL-Behring) to the 2-fold diluted blood of (1); (3) blood prepared by adding a 0.5 U PCC formulation (CSL-Behring) to the 2-fold diluted blood of (1); (4) blood prepared by adding 1 U heparin; or (5) blood prepared by adding 3 μg/ml Abciximab (Eli Lilly). .. The same experiment as in Example 4-1 was carried out using (1) blood prepared by 2-fold dilution of the citrate blood with physiological saline; (2) blood prepared by adding a 0.5 U vWF (von Willebrand factor) formulation (CSL-Behring) to the 2-fold diluted blood of (1); (3) blood prepared by adding a 0.5 U PCC formulation (CSL-Behring) to the 2-fold diluted blood of (1); (4) blood prepared by adding 1 U heparin; or (5) blood prepared by adding 3 μg/ml Abciximab (Eli Lilly).

    Periodic Counter-current Chromatography:

    Article Title: Microchip for assay of blood properties, and device for assay of blood properties
    Article Snippet: Blood was collected using a blood collection tube containing 3.2% sodium citrate, manufactured by Terumo Corporation. .. The same experiment as in Example 4-1 was carried out using (1) blood prepared by 2-fold dilution of the citrate blood with physiological saline; (2) blood prepared by adding a 0.5 U vWF (von Willebrand factor) formulation (CSL-Behring) to the 2-fold diluted blood of (1); (3) blood prepared by adding a 0.5 U PCC formulation (CSL-Behring) to the 2-fold diluted blood of (1); (4) blood prepared by adding 1 U heparin; or (5) blood prepared by adding 3 μg/ml Abciximab (Eli Lilly). .. The same experiment as in Example 4-1 was carried out using (1) blood prepared by 2-fold dilution of the citrate blood with physiological saline; (2) blood prepared by adding a 0.5 U vWF (von Willebrand factor) formulation (CSL-Behring) to the 2-fold diluted blood of (1); (3) blood prepared by adding a 0.5 U PCC formulation (CSL-Behring) to the 2-fold diluted blood of (1); (4) blood prepared by adding 1 U heparin; or (5) blood prepared by adding 3 μg/ml Abciximab (Eli Lilly).

    Concentration Assay:

    Article Title: Arachidonic acid causes lysis of blood cells and ADP-dependent platelet activation responses in platelet function tests.
    Article Snippet: Some control experiments were also performed using AA from other manufacturers (Hart Biologicals, Hartlepool, UK, and DiaSys/ Rolf Greiner Biochemica, Flacht, Germany). .. In parallel, whole blood or PRP samples were treated with abciximab (Eli Lilly, Indianapolis, IN, USA, final concentration 20 μg/mL) and incubated in the aggregometers with the same stirring and temperature conditions as for aggregating samples. ..

    Incubation:

    Article Title: Arachidonic acid causes lysis of blood cells and ADP-dependent platelet activation responses in platelet function tests.
    Article Snippet: Some control experiments were also performed using AA from other manufacturers (Hart Biologicals, Hartlepool, UK, and DiaSys/ Rolf Greiner Biochemica, Flacht, Germany). .. In parallel, whole blood or PRP samples were treated with abciximab (Eli Lilly, Indianapolis, IN, USA, final concentration 20 μg/mL) and incubated in the aggregometers with the same stirring and temperature conditions as for aggregating samples. ..



    Similar Products

    abciximab  (MedChemExpress)
    93
    MedChemExpress abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/Abciximab/pmc12478252-44-0-9
    Average 93 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    abciximab  (Biocon Inc)
    90
    Biocon Inc abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by Biocon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/abciximab/pm40525526-28-3-7
    Average 90 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    reopro® (abciximab) antibody  (Centocor Inc)
    90
    Centocor Inc reopro® (abciximab) antibody
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Reopro® (Abciximab) Antibody, supplied by Centocor Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/abciximab+reopro/us12195475-352-32-37
    Average 90 stars, based on 1 article reviews
    reopro® (abciximab) antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    abciximab  (Eli Lilly)
    86
    Eli Lilly abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/abciximab/10__1155_slash_jocs_slash_3615306-93-3-5
    Average 86 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    abciximab reopro  (Eli Lilly)
    90
    Eli Lilly abciximab reopro
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/abciximab+reopro/pm39701440-16-10-12
    Average 90 stars, based on 1 article reviews
    abciximab reopro - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    abciximab  (Mager Scientific)
    90
    Mager Scientific abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by Mager Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/abciximab/pmc11589161__41467_2024_54309_MOESM3_ESM-1321-16-22
    Average 90 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    monoclonal antibody abciximab reopro  (Eli Lilly)
    90
    Eli Lilly monoclonal antibody abciximab reopro
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Monoclonal Antibody Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/monoclonal+antibody+abciximab+reopro/pm39170431-50-1-7
    Average 90 stars, based on 1 article reviews
    monoclonal antibody abciximab reopro - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    glycoprotein iib/iiia inhibitor abciximab reopro  (Eli Lilly)
    90
    Eli Lilly glycoprotein iib/iiia inhibitor abciximab reopro
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Glycoprotein Iib/Iiia Inhibitor Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abciximab/glycoprotein+iib+iiia+inhibitor+abciximab+reopro/pm38916492-101-6-11
    Average 90 stars, based on 1 article reviews
    glycoprotein iib/iiia inhibitor abciximab reopro - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

    Journal: Blood Vessels, Thrombosis & Hemostasis

    Article Title: Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents

    doi: 10.1016/j.bvth.2025.100096

    Figure Lengend Snippet: Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

    Article Snippet: Abciximab (anti-αIIbβ3 inhibitory antibody, clone C7E3) was purchased from MedChemExpress LLC (Monmouth Junction, NJ).

    Techniques: Inhibition, Incubation, Labeling